Nail outcome improvements with certolizumab pegol in moderate to severe plaque psoriasis: results from phase 3 trials

被引：0
|
作者：
Gottlieb, A. B. [1 ]
Thaci, D. [2 ]
Leonardi, C. [3 ,4 ]
Poulin, Y. [5 ]
Kavanagh, S. [6 ]
Boehnlein, M. [7 ]
Reich, K. [8 ,9 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Lubeck, Lubeck, Germany
[3] Cent Dermatol, St Louis, MO USA
[4] St Louis Univ, Sch Med, St Louis, MO USA
[5] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[6] UCB Pharma, Raleigh, NC USA
[7] UCB Pharma, Monheim, Germany
[8] SCIderm Res Inst, Hamburg, Germany
[9] Dermatologikum Berlin, Berlin, Germany
来源：
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2019年 / 33卷
关键词：
Certolizumab Pegol; Nail disease; Psoriasis;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P116
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [1] Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
    Lee, Arnold
    Scott, Lesley J.
    [J]. BIODRUGS, 2020, 34 (02) : 235 - 244
  • [2] Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
    Arnold Lee
    Lesley J. Scott
    [J]. BioDrugs, 2020, 34 : 235 - 244
  • [3] Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
    Umezawa, Yoshinori
    Sakurai, Shinya
    Hoshii, Naoki
    Nakagawa, Hidemi
    [J]. DERMATOLOGY AND THERAPY, 2021, 11 (02) : 513 - 528
  • [4] Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
    Yoshinori Umezawa
    Shinya Sakurai
    Naoki Hoshii
    Hidemi Nakagawa
    [J]. Dermatology and Therapy, 2021, 11 : 513 - 528
  • [5] Fatigue in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from the CIMPACT phase 3 trial
    Gottlieb, Alice B.
    Soung, Jennifer
    Pinter, Andreas
    Tsai, Tsen-Fang
    Carrascosa, Jose Manuel
    Maul, Julia-Tatjana
    Khattri, Saakshi
    Tilt, Nicola
    Lopez Pinto, Jose M.
    Hellot, Scarlett
    Merola, Joseph F.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB168 - AB168
  • [6] Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: An overview of 3 randomized controlled trials
    Blauvelt, Andrew
    Reich, Kristian
    Drew, Janice
    Peterson, Luke
    Lebwohl, Mark
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB239 - AB239
  • [7] Safety of certolizumab pegol over 48 weeks in plaque psoriasis phase 3 trials
    Blauvelt, A.
    Strober, B.
    Langley, R.
    Burge, D.
    Pisenti, L.
    Yassine, M.
    Kavanagh, S.
    Arendt, C.
    Rolleri, R.
    Lebwohl, M.
    Reich, K.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 21 - 21
  • [8] Improvements in anxiety and depression among patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from 2 phase 3 trials (CIMPASI-1 and CIMPASI-2)
    Armstrong, April
    McBride, Sandra
    Spelman, Lynda
    Fernandez-Penas, Pablo
    Rich, Phoebe
    Martin, George
    Tilt, Nicola
    Pinto, Jose M. Lopez
    Popova, Christina
    Hellot, Scarlett
    Wilsmann-Theis, Dagmar
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB175 - AB175
  • [9] BUDGET IMPACT ANALYSIS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Tzanetakos, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S422 - S422
  • [10] COST-EFFECTIVENESS OF CERTOLIZUMAB PEGOL FOR THE TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN GREECE
    Gourzoulidis, G.
    Rigopoulos, D.
    Kountouris, V
    Christou, P.
    Kiri, S.
    Tzanetakos, C.
    [J]. VALUE IN HEALTH, 2019, 22 : S422 - S422
12345